Fostamatinib was approved by the U.S. Food and Drug Administration (FDA) in April 2018, mainly for the treatment of adult patients with chronic immune thrombocytopenia (ITP) who have not responded well to previous treatment. The dosage of Fostamatinib usually depends on the patient's specific situation, including the severity of the disease, physical condition and tolerance. The following article will give you a detailed introduction to the dosage and relevant precautions of Fostamatinib.

Dosage of Fostamatinib

The medication guidance of Fostamatinib is essential to ensure that patients receive treatment safely and effectively. The following is a detailed description of the dosage of Fostamatinib:

1. Starting dose

The recommended starting dose of Fostamatinib is 100 mg, orally, twice a day. This dose should be based on the patient's specific situation and the doctor's advice.

2. Dose adjustment

One month after the patient starts taking Fostamatinib, the doctor will re-evaluate the patient's platelet count. If the platelet count does not rise to 50×10^9/L or more, the dose of Fostamatinib should be increased to 150mg twice daily. This dose adjustment is to ensure that the drug can effectively increase the platelet count while also minimizing possible adverse reactions.

3. Maintenance dose

When patients are treated with the lowest dose of Fostamatinib, they should achieve and maintain a platelet count of 50x10^9/L or more, mainly to reduce the risk of bleeding in patients. The doctor will decide whether to continue to maintain this dose or make further adjustments based on the patient's specific response and medication safety.

4. Medication method

Fostamatinib can be taken with or without food. Patients can choose the time of medication according to their own eating habits, without special consideration of the effect of food on drug absorption.

5. Missed dose treatment

If the patient misses a dose of Fostamatinib, the patient should be instructed to take the next dose normally according to the medication plan. There is no need to double the dose to make up for the missed dose, so as not to increase the risk of adverse reactions.

The above information is for reference only. The specific dosage regimen of Fontantinib should be based on the patient's specific situation and the doctor's advice. During treatment with Fontantinib, patients should be evaluated by their doctors regularly to ensure the safe use of the drug. Patients should also pay close attention to their physical reactions and consult a doctor or pharmacist in a timely manner if they have any discomfort or questions.